Financial Performance - For the fiscal year ending March 31, 2024, the revenue was approximately HKD 648.4 million, an increase of about 24.6% compared to HKD 520.3 million in the same period of 2023[2] - The operating profit for the same year was approximately HKD 174.2 million, representing a significant increase of about 100.2% from HKD 87.0 million in 2023[2] - The profit attributable to equity holders was approximately HKD 130.5 million, up about 149.5% from the adjusted profit of HKD 52.3 million in 2023[2] - The total comprehensive income for the year was HKD 130.9 million, compared to HKD 52.9 million in the previous year[4] - Basic and diluted earnings per share were HKD 14.76, up from HKD 6.41 in the previous year[12] - Total revenue for the year ended March 31, 2024, reached HKD 648,415,000, a significant increase from HKD 520,323,000 in the previous year, representing a growth of approximately 24.6%[41] - Reported segment gross profit for the year ended March 31, 2024, was HKD 338,081,000, compared to HKD 205,509,000 for the previous year, indicating a year-over-year increase of about 64.1%[41] - The adjusted EBITDA for the year ended March 31, 2024, was HKD 215,496,000, compared to HKD 121,500,000 in the previous year, marking an increase of around 77.3%[41] - The company's profit attributable to equity holders for the year ended March 31, 2024, was HKD 130,463,000, compared to HKD 57,093,000 for the previous year, representing an increase of 128.5%[59] Dividends and Shareholder Returns - The board proposed a final dividend of HKD 0.0405 per share, totaling approximately HKD 33.8 million, compared to HKD 0.025 per share in the previous year[2] - The company declared an interim dividend of HKD 3.45 per share, significantly up from HKD 0.5 per share in the previous year, totaling HKD 29,871,000 compared to HKD 4,468,000[60] Assets and Liabilities - Non-current assets amounted to HKD 1,021.2 million, while current assets totaled HKD 367.5 million as of March 31, 2024[15] - Total liabilities were HKD 145.2 million, with non-current liabilities at HKD 94.3 million[17] - The total equity attributable to equity holders was HKD 970.7 million, down from HKD 985.5 million in the previous year[17] - The total designated non-current assets as of March 31, 2024, were valued at HKD 1,009,150,000, a slight decrease from HKD 1,053,069,000 in the previous year[45] - The company reported a net loss of HKD 4,468,000 from the sale of property, plant, and equipment, compared to a loss of HKD 126,000 in the previous year[47] - The company’s total liabilities increased significantly, reflecting a strategic shift in financial management and operational expansion[65] Revenue Segmentation - The group operates three reportable segments: branded pharmaceuticals, traditional Chinese medicine, and health products, with all business primarily conducted in Hong Kong[34][35] - Revenue from external customers in Hong Kong amounted to HKD 462,829,000 for the year ended March 31, 2024, up from HKD 331,887,000 in the previous year, reflecting a growth of approximately 39.5%[43] - The brand healthcare business recorded total revenue of HKD 648.4 million, a significant increase of 24.6% compared to the previous period[102] - The brand medicine segment achieved a remarkable revenue growth of 53.3%, driven by the strong performance of flagship product He Ji Gong[115] - The health supplement segment has shown remarkable growth, reflecting the company's proactive response to the post-pandemic market recovery, with significant increases in scar removal and health supplement brands[134] Market Strategy and Growth - The company plans to continue expanding its market presence and investing in new product development to drive future growth[41] - The company is strategically expanding its market share in the Greater Bay Area with its brand Chinese medicine products[155] - The company is focusing on developing its cross-border e-commerce platform to ensure sustainable growth[153] - The company is actively expanding the registration scope of its compound brand Chinese medicine pellets and developing new concentrated Chinese medicine products to meet market demand[177] - The company is collaborating with well-known brands to enhance its influence in the traditional Chinese medicine sector[97] Operational Efficiency and Cost Management - Employee costs and other production costs rose by HKD 9.2 million or 31.3% and HKD 2.9 million or 10.1%, respectively, due to increased production to meet market demand[164] - The company maintained a conservative capital management approach, ensuring a solid foundation for future business development and acquisitions[197] - Material costs accounted for approximately 77% of total sales costs in fiscal year 2024, decreasing by HKD 16.6 million or 6.5% from fiscal year 2023[186] Marketing and Brand Development - The company has implemented comprehensive marketing strategies, including sponsorship of the popular TV program "The Voice of Middle Age 2," to increase brand awareness across multiple platforms[120] - The company aims to enhance brand recognition and engage younger consumers through strategic brand building and innovative marketing campaigns[143] - The strong performance is attributed to effective execution of advertising and marketing strategies for key brands, particularly Baiji Pills and He Ji Gong[112] Future Outlook and Strategic Initiatives - The company expresses confidence in its strategy positioning to achieve sustained growth in the evolving market[82] - The company is committed to promoting preventive healthcare through community outreach and education, focusing on traditional Chinese medicine solutions[136] - The company remains vigilant in managing significant risks while preparing to seize growth opportunities amid complex geopolitical and economic conditions[129]
健倍苗苗(02161) - 2024 - 年度业绩